Positive NICE recommendation for Halaven for patients with locally advanced or metastatic breast cancer
Is the first breast cancer treatment to be recommended by NICE in nearly a decade.
The National Institute of Health and Care Excellence (NICE) has recommended Halaven (eribulin) for the treatment of locally advanced or metastatic breast cancer in a Final Appraisal Determination published today. Eribulin is the first breast cancer treatment to be recommended by NICE in nearly a decade.
Eribulin is indicated in the European Union (EU) for the treatment of adults with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting, unless patients were not suitable for these treatments. NICE has recommended Eribulin for the treatment of adults with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimen for advanced disease. Prior therapy may have included an anthracycline or a taxane, and capecitabine.
"Eribulin was approved in March 2011 and after years of uncertainty for patients and poor management of the Cancer Drugs Fund, people with locally advanced or metastatic breast cancer in England will finally now have routine access to eribulin. Over a period of more than 5 years, Eisai has shown great flexibility in pricing to maintain patient access to eribulin both in the CDF and with NICE and would like the same opportunity to enable access to our newer cancer drug lenvatinib for radioiodine refractory differentiated thyroid cancer patients, however so far an unacceptable process has again taken precedence over patients," comments Gary Hendler, Chairman & CEO Eisai EMEA.
Approximately 44,500 women are diagnosed with breast cancer in England each year, of whom one third subsequently develop metastatic disease. Only 15% of women with metastatic breast cancer will survive beyond 5 years. Eribulin is one of the most prescribed treatments within the CDF and to date approximately 4,000 patients have been able to access eribulin in the UK since 2011.
"I am delighted that women in England with locally advanced or metastatic breast cancer will continue to be able to access eribulin, and that the future of this treatment within the NHS is secure. Eribulin significantly improves overall survival in women with this disease and it is therefore an important option against breast cancer," comments Dr Mark Harries, Consultant Medical Oncologist.
Eribulin was first approved and launched in the UK in 2011 and marketing authorisation was extended for earlier use in advanced breast cancer from the European Commission on 3 July 2014. Eribulin is currently approved in more than 60 countries around the world including all of the EU, Canada, US, Russia, Switzerland, South Korea, Japan and Singapore.
Related News
-
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Novartis agrees for copies to be made of cancer drug to reach poorer countries
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute. -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance